naltrexone HCl

naltrexone HCl,

n brand names: ReVia, Trexan;
drug class: narcotic antagonist;
action: competes with opioids at opioid receptor sites;
uses: treatment of opioid addiction following detoxification.
References in periodicals archive ?
com/research/g7lhzm/global_and) has announced the addition of the "Global and Chinese Naltrexone HCL Industry Report 2014" report to their offering.
The Global and Chinese Naltrexone HCL Industry Report 2014 is a professional and in-depth study on the current state of the global naltrexone HCL industry with a focus on the Chinese situation.
The naltrexone HCL market analysis is provided for both the international and Chinese domestic situations including development trends, competitive landscape analysis, key regions development status and a comparison analysis between the international and Chinese markets.
Naltrexone HCL industry import/export consumption, supply and demand figures and cost price and production value gross margins are also provided.
The naltrexone HCL industry development trends and marketing channels are analyzed.
Chapter Two Naltrexone HCL International and China Market Analysis
Chapter Three Naltrexone HCL Technical Data and Manufacturing Plants Analysis
Chapter Four Naltrexone HCL Production by Regions By Technology By Applications
Chapter Five Naltrexone HCL Manufacturing Process and Cost Structure
Chapter Six 2009-2014 Naltrexone HCL Productions Supply Sales Demand Market Status and Forecast
Chapter Seven Naltrexone HCL Key Manufacturers Analysis
The company is pleased to announce that on April 3, 2013, it received acknowledgement from the Department of Health and Human Services confirming the FDA's receipt of the change in sponsorship of the IND application for Naltrexone HCL along with the orphan drug designation for both[met5]-enkephalin and low dose naltrexone (LDN) in the treatment of pediatric patients with Crohn's disease.